person · Reporting owner

Heffernan Michael Thomas

Disclosed activity across 9 companies

Tapewire entity: 37240
SEC CIK: 0001448914

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Akebia Therapeutics, Inc.AKBA · Entity 6105	Director	June 02, 2021	June 03, 2021
Avalo Therapeutics, Inc.AVTX · Entity 4936	Director	June 02, 2026	June 04, 2026
Biohaven Ltd.BHVN · Entity 4379	Director	April 28, 2026	May 01, 2026
Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269	Director	October 03, 2022	October 03, 2022
COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169	Director	February 10, 2025	February 12, 2025
SYNLOGIC, INC.SYBX · Entity 7801	Director	June 22, 2023	June 26, 2023
Trevi Therapeutics, Inc.TRVI · Entity 4387	Director	September 15, 2026	September 17, 2026
enGene Therapeutics Inc.ENGN · Entity 6638	Director	June 16, 2026	June 17, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akebia Therapeutics, Inc.

Report date June 02, 2021 · Filed June 03, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	48,586	Reported balance After 2021-06-02 transaction · row 1 1 source row Row 1 · 2021-06-02 · Grant · Acquired 13,700 · Balance 48,586 F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2031-06-02	Direct	20,100	Reported balance After 2021-06-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-02 · Grant · Acquired 20,100 · Balance 20,100 F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

Avalo Therapeutics, Inc.

Report date June 02, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.96 · Expires 2036-06-02	Direct	29,500	Reported balance After 2026-06-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-02 · Grant · Acquired 29,500 · Balance 29,500 F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

Biohaven Ltd.

Report date April 28, 2026 · Filed May 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28	Direct	68,693	Reported balance After 2026-04-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Biohaven Pharmaceutical Holding Co Ltd.

Report date October 03, 2022 · Filed October 03, 2022

Security / award	Ownership account	Disclosure context
Restricted Share Unit AwardSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-10-03 · Disposition to issuer · Disposed 3,320 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28	Direct	Reported balance After 2022-10-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05	Direct	Reported balance After 2022-10-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.30 · Expires 2030-01-31	Direct	Reported balance After 2022-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-03 · Disposition to issuer · Disposed 26,200 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

COLLEGIUM PHARMACEUTICAL, INC

Report date February 10, 2025 · Filed February 12, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	50,328	Reported balance After 2025-02-10 transaction · row 1 1 source row Row 1 · 2025-02-10 · Grant · Acquired 4,820 · Balance 50,328 F1: Reflects the grant of fully-vested restricted stock units ("RSUs") granted as compensation for the Reporting Person's service as interim Chief Executive Officer in 2024. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the grant of fully-vested restricted stock units ("RSUs") granted as compensation for the Reporting Person's service as interim Chief Executive Officer in 2024. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SYNLOGIC, INC.

Report date June 22, 2023 · Filed June 26, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-22	Direct	30,000	Reported balance After 2023-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-22 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

Trevi Therapeutics, Inc.

Report date September 15, 2026 · Filed September 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,351	Ending reported balance After 2026-09-15 transaction · row 6 6 source rows · reconciled sequence Row 1 · 2026-09-15 · Exercise / conversion · Acquired 18,421 · Balance 24,772 Row 2 · 2026-09-15 · Sale · Disposed 18,321 · Balance 6,451 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Row 3 · 2026-09-15 · Sale · Disposed 100 · Balance 6,351 F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Row 4 · 2026-09-15 · Exercise / conversion · Acquired 21,052 · Balance 27,403 Row 5 · 2026-09-15 · Sale · Disposed 20,952 · Balance 6,451 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Row 6 · 2026-09-15 · Sale · Disposed 100 · Balance 6,351 F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04	Direct	0	Reported balance After 2026-09-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-15 · Exercise / conversion · Disposed 18,421 · Balance 0 F3: These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. F4: These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33	Direct	0	Reported balance After 2026-09-15 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-09-15 · Exercise / conversion · Disposed 21,052 · Balance 0 F5: These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. F6: These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3: These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments.

F4: These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027.

F5: These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments.

F6: These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027.

enGene Therapeutics Inc.

Report date June 16, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2036-06-16	Direct	31,000	Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 31,000 · Balance 31,000 F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

KERYX BIOPHARMACEUTICALS INC

Report date December 12, 2018 · Filed December 13, 2018

Section 16 reporting ended · disclosed 2018-12-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-12-12 transaction · row 1 1 source row Row 1 · 2018-12-12 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 16,666 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018.
Stock OptionSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-12-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-12-12 · Disposition to issuer · Disposed 110,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement.

F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 16,666 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018.

F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 30, 2018 Filed Jul 12, 2018 17:59 UTC	KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001114220-18-000074 · wf-form4_153143273940791.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 30, 2019, June 30, 2020 and June 30, 2021. F2 · balance_after: Includes 10,666 shares of restricted stock. Read SEC document
June 12, 2018 Filed Jun 13, 2018 20:56 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	SaleCommon Stock	53,057	$25.26	$1,340,219.82	Disclosure SEC source: 0001192482-18-000290 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,693 F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.52, inclusive. Read SEC document
June 11, 2018 Filed Jun 13, 2018 20:56 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	SaleCommon Stock	96,943	$25.28	$2,450,719.04	Disclosure SEC source: 0001192482-18-000290 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,750 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2). Read SEC document
May 10, 2018 Filed May 14, 2018 20:32 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	SaleCommon Stock	1,500	$27.00	$40,500.00	Disclosure SEC source: 0001192482-18-000202 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,693 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2016, as amended. Read SEC document
May 10, 2018 Filed May 14, 2018 20:32 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	SaleCommon Stock	5,600	$26.00	$145,600.00	Disclosure SEC source: 0001192482-18-000202 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,193 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2016, as amended. Read SEC document
April 19, 2018 Filed Apr 23, 2018 21:05 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	SaleCommon Stock	100	$26.01	$2,601.00	Disclosure SEC source: 0001192482-18-000165 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,793 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2016, as amended. Read SEC document
April 19, 2018 Filed Apr 23, 2018 21:05 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	SaleCommon Stock	44,300	$26.00	$1,151,800.00	Disclosure SEC source: 0001192482-18-000165 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,893 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2016, as amended. Read SEC document
February 26, 2018 Filed Mar 1, 2018 21:04 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	Tax withholdingCommon Stock	4,050	$21.77	$88,168.50	Disclosure SEC source: 0001192482-18-000099 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,193 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document
February 05, 2018 Filed Feb 6, 2018 21:14 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	Tax withholdingCommon Stock	788	$23.38	$18,423.44	Disclosure SEC source: 0001192482-18-000074 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,243 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document
January 26, 2018 Filed Jan 30, 2018 00:41 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	1,044	$10.17	$10,617.48	Disclosure SEC source: 0001192482-18-000067 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,031 F2 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
January 25, 2018 Filed Jan 30, 2018 00:41 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantStock Option (Right to Purchase) · Derivative	150,000	$0.00 Strike: $24.35	$0.00	Disclosure SEC source: 0001192482-18-000067 · edgar.xml · derivative · entry 3 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-01-25 F3 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2018. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2019, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer. Read SEC document
January 25, 2018 Filed Jan 30, 2018 00:41 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	75,000	$0.00	$0.00	Disclosure SEC source: 0001192482-18-000067 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,987 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2018. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2019, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock. Read SEC document
January 23, 2018 Filed Jan 23, 2018 22:41 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	SaleCommn Stock	16,408	$25.01	$410,364.08	Disclosure SEC source: 0001192482-18-000054 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,987 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2016, as amended. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 22, 2018 Filed Jan 23, 2018 22:41 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	SaleCommon Stock	3,592	$25.00	$89,800.00	Disclosure SEC source: 0001192482-18-000054 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 535,395 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2016, as amended. Read SEC document
January 19, 2018 Filed Jan 19, 2018 22:41 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	SaleCommon Stock	20,000	$22.50	$450,000.00	Disclosure SEC source: 0001192482-18-000046 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,987 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2016, as amended. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.50 to $22.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 15, 2017 Filed Nov 18, 2017 02:04 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	SaleCommon Stock	50,000	$15.53	$776,500.00	Disclosure SEC source: 0001192482-17-000277 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,987 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2016, as amended. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.50 to $15.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 04, 2017 Filed Aug 4, 2017 20:17 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	Tax withholdingCommon Stock	736	$12.39	$9,119.04	Disclosure SEC source: 0001192482-17-000216 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,987 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document
July 28, 2017 Filed Aug 4, 2017 20:17 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	640	$10.60	$6,784.00	Disclosure SEC source: 0001192482-17-000216 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,723 F1 · kind: Shares acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
June 09, 2017 Filed Jun 20, 2017 16:12 UTC	KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794	GrantStock Options (right to buy) · Derivative	30,000	$0.00 Strike: $6.56	$0.00	Disclosure SEC source: 0000899243-17-016764 · doc4.xml · derivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-09 F3 · derivative.exercise_date: The 30,000 stock options vest as to one-third on each of June 9, 2018, June 9, 2019 and June 9, 2020. Read SEC document
June 09, 2017 Filed Jun 20, 2017 16:12 UTC	KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0000899243-17-016764 · doc4.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 9, 2018, June 9, 2019 and June 9, 2020. F2 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document
March 17, 2017 Filed Mar 21, 2017 20:45 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	Tax withholdingCommon Stock	1,472	$14.95	$22,006.40	Disclosure SEC source: 0001192482-17-000088 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,083 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document
February 10, 2017 Filed Feb 14, 2017 22:54 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantStock Option (Right to Purchase) · Derivative	110,000	$0.00 Strike: $15.27	$0.00	Disclosure SEC source: 0001192482-17-000041 · edgar.xml · derivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2027-02-10 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. Read SEC document
February 10, 2017 Filed Feb 14, 2017 22:54 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	55,000	$0.00	$0.00	Disclosure SEC source: 0001192482-17-000041 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,555 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock. Read SEC document
January 31, 2017 Filed Feb 2, 2017 21:26 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	Exercise / conversionStock Option (Right to Purchase) · Derivative	3,013	$0.00 Strike: $0.48	$0.00	Disclosure SEC source: 0001192482-17-000027 · edgar.xml · derivative · entry 3 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,013 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the 3,013 option shares are exercisable. Read SEC document
January 31, 2017 Filed Feb 2, 2017 21:26 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	Exercise / conversionCommon Stock	3,013	$0.48	$1,446.24	Disclosure SEC source: 0001192482-17-000027 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 27, 2017 Filed Feb 2, 2017 21:26 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	1,239	$10.08	$12,489.12	Disclosure SEC source: 0001192482-17-000027 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,542 F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.